BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 38622605)

  • 1. Guanylate-Binding Protein 1: An Emerging Target in Inflammation and Cancer.
    Honkala AT; Tailor D; Malhotra SV
    Front Immunol; 2019; 10():3139. PubMed ID: 32117203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
    Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
    Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-γ-induced GBP1 is an inhibitor of human papillomavirus 18.
    Xu M; Lin MC; Li ZH
    BMC Womens Health; 2024 Apr; 24(1):240. PubMed ID: 38622605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.
    Peng S; Ferrall L; Gaillard S; Wang C; Chi WY; Huang CH; Roden RBS; Wu TC; Chang YN; Hung CF
    mBio; 2021 Jan; 12(1):. PubMed ID: 33468698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Messenger ribonucleic acid encoding interferon-inducible guanylate binding protein 1 is induced in human endometrium within the putative window of implantation.
    Kumar S; Li Q; Dua A; Ying YK; Bagchi MK; Bagchi IC
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2420-7. PubMed ID: 11397834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-Risk Mucosal Human Papillomavirus 16 (HPV16) E6 Protein and Cutaneous HPV5 and HPV8 E6 Proteins Employ Distinct Strategies To Interfere with Interferon Regulatory Factor 3-Mediated Beta Interferon Expression.
    Poirson J; Suarez IP; Straub ML; Cousido-Siah A; Peixoto P; Hervouet E; Foster A; Mitschler A; Mukobo N; Chebaro Y; Garcin D; Recberlik S; Gaiddon C; Altschuh D; Nominé Y; Podjarny A; Trave G; Masson M
    J Virol; 2022 May; 96(10):e0187521. PubMed ID: 35475668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell-mediated immune responses to human papillomavirus 16 E6 and E7 antigens as measured by interferon gamma enzyme-linked immunospot in women with cleared or persistent human papillomavirus infection.
    Farhat S; Nakagawa M; Moscicki AB
    Int J Gynecol Cancer; 2009 May; 19(4):508-12. PubMed ID: 19509544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IFN-gamma produced by human papilloma virus-18 E6-specific CD4+ T cells predicts the clinical outcome after surgery in patients with high-grade cervical lesions.
    Seresini S; Origoni M; Lillo F; Caputo L; Paganoni AM; Vantini S; Longhi R; Taccagni G; Ferrari A; Doglioni C; Secchi P; Protti MP
    J Immunol; 2007 Nov; 179(10):7176-83. PubMed ID: 17982110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HPV16 E6 promoting cervical cancer progression through down-regulation of miR-320a to increase TOP2A expression.
    Zhang J; Yu X; Guo Y; Wang D
    Cancer Med; 2024 Feb; 13(3):e6875. PubMed ID: 38205938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HPV E6/E7: insights into their regulatory role and mechanism in signaling pathways in HPV-associated tumor.
    Peng Q; Wang L; Zuo L; Gao S; Jiang X; Han Y; Lin J; Peng M; Wu N; Tang Y; Tian H; Zhou Y; Liao Q
    Cancer Gene Ther; 2024 Jan; 31(1):9-17. PubMed ID: 38102462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activating STING/TBK1 suppresses tumor growth via degrading HPV16/18 E7 oncoproteins in cervical cancer.
    Huang X; Huo L; Xiao B; Ouyang Y; Chen F; Li J; Zheng X; Wei D; Wu Y; Zhang R; Cao X; Kang T; Gao Y
    Cell Death Differ; 2024 Jan; 31(1):78-89. PubMed ID: 38007552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignancy Associated with Low-Risk HPV6 and HPV11: A Systematic Review and Implications for Cancer Prevention.
    Silva LLD; Teles AM; Santos JMO; Souza de Andrade M; Medeiros R; Faustino-Rocha AI; Oliveira PA; Dos Santos APA; Ferreira Lopes F; Braz G; Brito HO; Costa RMGD
    Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cervical Cancer Screening: A Review.
    Perkins RB; Wentzensen N; Guido RS; Schiffman M
    JAMA; 2023 Aug; 330(6):547-558. PubMed ID: 37552298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human papillomavirus E5 suppresses immunity via inhibition of the immunoproteasome and STING pathway.
    Miyauchi S; Kim SS; Jones RN; Zhang L; Guram K; Sharma S; Schoenberger SP; Cohen EEW; Califano JA; Sharabi AB
    Cell Rep; 2023 May; 42(5):112508. PubMed ID: 37171962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human papillomavirus vaccination and cervical cancer risk.
    Rahangdale L; Mungo C; O'Connor S; Chibwesha CJ; Brewer NT
    BMJ; 2022 Dec; 379():e070115. PubMed ID: 36521855
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.